T. Rowe Price, an American publicly owned global investment management firm, led a $518m Series B financing round in Eikon Therapeutics, a pioneer in the application of live-cell super-resolution microscopy to drug discovery, with participation from Canada Pension Plan Investment Board, EcoR1 Capital, UC Investments, Abu Dhabi Investment Authority, StepStone Group, Soros Capital, Schroders Capital, Harel Insurance, General Catalyst, E15 VC, Hartford HealthCare Endowment, AME Cloud Ventures, The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital and Horizons Ventures. “With the support of our investors, we continue to make dramatic progress in the industrialization of our live-cell imaging platform. We will use the resources of this new financing to progress more quickly toward our mission of inventing innovative medicines that will improve and extend life,” Roger M. Perlmutter, Eikon Therapeutics CEO and Chairman.